LANSING, Mich., April 23, 2008 (PRIME NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) is pleased to announce that as a result of the discovery of diagnostic testing applications for genetically engineered spider-silk polymers, the company intends to vigorously pursue commercial applications in the lucrative diagnostic testing market. This will add another future revenue possibility to Kraig's multi-channel efforts to commercialize their spider-silk technology in textile, homeland defense, and personal security, among others.
"Through our sponsored research program at the University of Notre Dame we were able to identify the potential of protein based fibers (polymers) to incorporate antigens through genetic engineering," stated Kraig Biocraft Laboratories' CEO, Kim Thompson. "By modifying recombinant fiber to react to various molecules, we should be able to successfully test for the targeted molecules, which could provide highly useful diagnostic data in a multitude of medical and health care applications. The recently announced provisional patent application, which was filed by the University pursuant to our collaborative research and intellectual property agreement, is a watershed event for our revolutionary technology and its broad commercial possibilities."
"The market for diagnostic testing is bolstered by the enormous demographic of aging baby boomers. Kraig is elated to be working on a new recombinant technology with the potential to service this growing market," Thompson added. "Of course, our collaborative research with leading universities has been critical to our successes."
Kraig Biocraft Laboratories is a biotechnology company focused on the development of commercially significant high-performance polymers and technical fiber. Based on proprietary genetic engineering technology, Kraig is working to develop and produce polymers and protein-based materials including Spider Silk.
For more information on Kraig Biocraft Laboratories please visit the Company's web site: http://www.KraigLabs.com
The Kraig Biocraft Laboratories, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4817
Statements in this press release about the company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "efforts," "foresees," "future", "forecasts," "estimates", "intends," "develops," "researching," "research," "goal," "potential," "possibility," "pursue," "could", "should" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions, marketing strategies, or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products and execute on its marketing plans may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.